Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 420

1.

Brooke-Spiegler syndrome presenting multiple concurrent cutaneous and parotid gland neoplasms: Cytologic findings on fine-needle sample and description of a novel mutation of the CYLD gene.

Malzone MG, Campanile AC, Losito NS, Longo F, Perri F, Caponigro F, Schiavone C, Ionna F, Maiello F, Martinuzzi C, Nasti S, Botti G, Fulciniti F.

Diagn Cytopathol. 2015 May 21. doi: 10.1002/dc.23275. [Epub ahead of print]

PMID:
25995191
2.

AXL is an oncotarget in human colorectal cancer.

Martinelli E, Martini G, Cardone C, Troiani T, Liguori G, Vitagliano D, Napolitano S, Morgillo F, Rinaldi B, Melillo RM, Liotti F, Nappi A, Bianco R, Berrino L, Ciuffreda LP, Ciardiello D, Iaffaioli V, Botti G, Ferraiolo F, Ciardiello F.

Oncotarget. 2015 Apr 29. [Epub ahead of print]

3.

Synchronous Pleomorphic Adenoma and Invasive Ductal Carcinoma in Distinct Breasts.

Di Bonito M, Cantile M, Cerrone M, Liguori G, Botti G.

Breast J. 2015 May 3. doi: 10.1111/tbj.12426. [Epub ahead of print] No abstract available.

PMID:
25940209
4.

Midface rejuvenation: a critical evaluation of a 7-year experience.

Pascali M, Botti C, Cervelli V, Botti G.

Plast Reconstr Surg. 2015 May;135(5):1305-16. doi: 10.1097/PRS.0000000000001189.

PMID:
25919244
5.

Heterogeneity of KRAS, NRAS, BRAF and PIK3CA mutations in metastatic colorectal cancer and potential effects on therapy in the CAPRI GOIM trial.

Normanno N, Rachiglio AM, Lambiase M, Martinelli E, Fenizia F, Esposito C, Roma C, Troiani T, Rizzi D, Tatangelo F, Botti G, Maiello E, Colucci G, Ciardiello F; on the behalf of the CAPRI-GOIM investigators.

Ann Oncol. 2015 Apr 7. pii: mdv176. [Epub ahead of print]

PMID:
25851630
6.

Factors predictive of pelvic lymph node involvement and outcomes in melanoma patients with metastatic sentinel lymph node of the groin: A multicentre study.

Mozzillo N, Pasquali S, Santinami M, Testori A, Di Marzo M, Crispo A, Patuzzo R, Verrecchia F, Botti G, Montella M, Rossi CR, Caracò C.

Eur J Surg Oncol. 2015 Mar 11. pii: S0748-7983(15)00078-5. doi: 10.1016/j.ejso.2015.02.005. [Epub ahead of print]

PMID:
25800935
7.

AurkA inhibitors enhance the effects of B-RAF and MEK inhibitors in melanoma treatment.

Caputo E, Miceli R, Motti ML, Taté R, Fratangelo F, Botti G, Mozzillo N, Carriero MV, Cavalcanti E, Palmieri G, Ciliberto G, Pirozzi G, Ascierto PA.

J Transl Med. 2015;13:2069. doi: 10.1186/1479-5876-13-S1-P1. No abstract available.

8.

Combined papillary and mucoepidermoid carcinoma of the thyroid gland: a possible collision tumor diagnosed on fine-needle cytology. Report of a case with immunocytochemical and molecular correlations.

Fulciniti F, Vuttariello E, Calise C, Monaco M, Pezzullo L, Chiofalo MG, Di Gennaro F, Malzone MG, Campanile AC, Losito NS, Botti G, Chiappetta G.

Endocr Pathol. 2015 May;26(2):140-4. doi: 10.1007/s12022-015-9364-9.

PMID:
25771987
9.

Activating PIK3CA mutations coexist with BRAF or NRAS mutations in a limited fraction of melanomas.

Manca A, Lissia A, Capone M, Ascierto PA, Botti G, Caracò C, Stanganelli I, Colombino M, Sini M, Cossu A, Palmieri G.

J Transl Med. 2015 Jan 28;13:37. doi: 10.1186/s12967-015-0401-8.

10.

HtrA1 loss is related to aggressive behavior parameters in sentinel node positive breast cancer.

Franco R, Collina F, Di Bonito M, Botti G, Montanaro D, Di Maio L, Vincenzi B, Landi G, D'Aiuto M, Caraglia M, Baldi A.

Histol Histopathol. 2015 Jun;30(6):707-14. doi: 10.14670/HH-30.707. Epub 2014 Dec 22.

PMID:
25530301
11.

Weekly docetaxel versus CMF as adjuvant chemotherapy for older women with early breast cancer: final results of the randomized phase III ELDA trial.

Perrone F, Nuzzo F, Di Rella F, Gravina A, Iodice G, Labonia V, Landi G, Pacilio C, Rossi E, De Laurentiis M, D'Aiuto M, Botti G, Forestieri V, Lauria R, De Placido S, Tinessa V, Daniele B, Gori S, Colantuoni G, Barni S, Riccardi F, De Maio E, Montanino A, Morabito A, Daniele G, Di Maio M, Piccirillo MC, Signoriello S, Gallo C, de Matteis A.

Ann Oncol. 2015 Apr;26(4):675-82. doi: 10.1093/annonc/mdu564. Epub 2014 Dec 8.

PMID:
25488686
12.

Ran signaling in melanoma: implications for the development of alternative therapeutic strategies.

Caputo E, Wang E, Valentino A, Crispi S, De Giorgi V, Fico A, Ficili B, Capone M, Anniciello A, Cavalcanti E, Botti G, Mozzillo N, Ascierto PA, Marincola FM, Travali S.

Cancer Lett. 2015 Feb 1;357(1):286-96. doi: 10.1016/j.canlet.2014.11.033. Epub 2014 Nov 20.

PMID:
25444926
13.

Phase 1/2 study of valproic acid and short-course radiotherapy plus capecitabine as preoperative treatment in low-moderate risk rectal cancer-V-shoRT-R3 (Valproic acid--short Radiotherapy--rectum 3rd trial).

Avallone A, Piccirillo MC, Delrio P, Pecori B, Di Gennaro E, Aloj L, Tatangelo F, D'Angelo V, Granata C, Cavalcanti E, Maurea N, Maiolino P, Bianco F, Montano M, Silvestro L, Terranova Barberio M, Roca MS, Di Maio M, Marone P, Botti G, Petrillo A, Daniele G, Lastoria S, Iaffaioli VR, Romano G, Caracò C, Muto P, Gallo C, Perrone F, Budillon A.

BMC Cancer. 2014 Nov 24;14:875. doi: 10.1186/1471-2407-14-875.

14.

KIT genetic alterations in anorectal melanomas.

Santi R, Simi L, Fucci R, Paglierani M, Pepi M, Pinzani P, Merelli B, Santucci M, Botti G, Urso C, Massi D.

J Clin Pathol. 2015 Feb;68(2):130-4. doi: 10.1136/jclinpath-2014-202572. Epub 2014 Nov 14.

PMID:
25398993
15.

Borderline Brenner tumor of the ovary: a case report with immunohistochemical and molecular study.

De Cecio R, Cantile M, Collina F, Marra L, Santonastaso C, Scaffa C, Botti G, Losito NS.

J Ovarian Res. 2014 Oct 29;7:101. doi: 10.1186/s13048-014-0101-7.

16.

Metabolic syndrome-breast cancer link varies by intrinsic molecular subtype.

Capasso I, Esposito E, de Laurentiis M, Maurea N, Cavalcanti E, Botti G, Petrillo A, Montella M, D'Aiuto M, Coppola C, Crispo A, Grimaldi M, Frasci G, Fucito A, Ciliberto G, D'Aiuto G.

Diabetol Metab Syndr. 2014 Sep 26;6(1):105. doi: 10.1186/1758-5996-6-105. eCollection 2014.

17.

Role of the cystathionine γ lyase/hydrogen sulfide pathway in human melanoma progression.

Panza E, De Cicco P, Armogida C, Scognamiglio G, Gigantino V, Botti G, Germano D, Napolitano M, Papapetropoulos A, Bucci M, Cirino G, Ianaro A.

Pigment Cell Melanoma Res. 2015 Jan;28(1):61-72. doi: 10.1111/pcmr.12312. Epub 2014 Oct 6.

PMID:
25205294
18.

Midface lift: our current approaches.

Botti G, Botti C.

Handchir Mikrochir Plast Chir. 2014 Aug;46(4):224-33. doi: 10.1055/s-0034-1385927. Epub 2014 Aug 27.

PMID:
25162240
19.

AurkA inhibitors enhance the effects of B-RAF and MEK inhibitors in melanoma treatment.

Caputo E, Miceli R, Motti ML, Taté R, Fratangelo F, Botti G, Mozzillo N, Carriero MV, Cavalcanti E, Palmieri G, Ciliberto G, Pirozzi G, Ascierto PA.

J Transl Med. 2014 Jul 31;12:216. doi: 10.1186/s12967-014-0216-z.

20.

Coexistence of granular cell tumor and invasive ductal breast cancer in contralateral breasts: a case report.

Di Bonito M, Cantile M, Collina F, De Cecio R, Petrosino T, Botti G.

Int J Mol Sci. 2014 Jul 25;15(8):13166-71. doi: 10.3390/ijms150813166.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk